D-0295-2019 Class III Terminated
FDA drug recall D-0295-2019 was initiated by QuVa Pharma, Inc. on Nov 21, 2018 and is designated Class III. Reason for recall: Incorrect excipient: Product was compounded in 250 mL 5% Dextrose instead of 250 mL 0.9% Sodium Chloride The recall status is terminated (terminated May 1, 2019). Affected quantity: 168 bags.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 19, 2018
- Initiation Date
- Nov 21, 2018
- Termination Date
- May 1, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 168 bags
Product description
Norepinephrine 8 mg (32 mcg/mL) added to 0.9% Sodium Chloride Injection 250 mL Bag, Rx only, Compounded by: QuVA Pharma 1075 West Park One Drive Suite 100 Sugar Land, TX 77478. Product Code 70092-9035-05
Reason for recall
Incorrect excipient: Product was compounded in 250 mL 5% Dextrose instead of 250 mL 0.9% Sodium Chloride
Distribution pattern
CA only
Code information
Lot #:10016014 Exp. 01/06/2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0295-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026